Breath Diagnostics has become one of the first companies to start using a highly advanced new machine for detecting lung cancer biomarkers.
Developed by analytical instrument expert Waters Corp (NYSE: WAT) (FRA: WAZ), the Xevo TQ Absolute XR Triple Quadrupole Mass Spectrometer (TQMS) is one of most sensitive and compact devices of its kind on the market today.
It was launched at the American Society for Mass Spectrometry’s conference in June. It provides up to a six-fold boost in performance in comparison to its predecessor machine: the Xevo TQ Absolute. Furthermore, the device uses up to 50 per cent less power and nitrogen gas while producing half as much heat as other brands.
Tandem quadrupole mass spectrometry is a powerful tool used to detect and quantify trace-level volatile organic compounds (VOC) in various samples. In the context of a lung cancer breath test like OneBreath, the Waters machine will help Breath Diagnostics to identify specific VOC biomarkers present in elevated levels due to metabolic changes in cancer cells.
“This powerful instrument will help us detect even the faintest molecular signals in a single breath, advance our biomarker discovery for diseases like lung cancer and pneumonia and move faster toward real-world, point-of-care applications,” said Breath Diagnostics.
Exhaled breath contains hundreds of VOCs originating from processes such as oxidation, inflammation and tumour metabolism. Lung cancer alters their composition in a distinct manner. It can be accurately identified through the use of the advanced screening system Breath Diagnostics has pioneered, which is now being complemented by the latest and greatest in mass spectrometry tech.
“With the Xevo TQ Absolute XR, we’re ready to take the next big step in unlocking the diagnostic power of breath,” Breath Diagnostics added.
To summarize, the TQMS machine is helping Breath Diagnostics revolutionize lung cancer screening with a precise VOC profiling tool that is being tailored for pinpointing lung cancer and respiratory diseases. Future integration with artificial intelligence could enhance its rate of accuracy even more, potentially accelerating widespread adoption.
Breath Diagnostics recently completed a groundbreaking study on its OneBreath technology’s ability to predict pneumonia onset in surgery patients. It was published in The Journal of Thoracic and Cardiovascular Surgery on Jul. 2.
The medtech operator also launched a Reg CF fundraising this year. Investors now have the opportunity to hold a stake in a lung cancer screening company that is breaking new ground in the field.
Read more: Breath Diagnostics tech achieves pneumonia prediction breakthrough in peer-reviewed study
Read more: Breath Diagnostics leader speaks at lung cancer education event in Louisville
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
